High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$10.7M
$10,737,871
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-03-05
$213,177x4
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-03-05 | $213,177x4 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-03-04
$204,508x8
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-03-04 | $204,508x8 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-03-03
$528,189x4
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-03-03 | $528,189x4 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-03-02
$523,584x10
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-03-02 | $523,584x10 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-02-17
$677,532
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-02-17 | $677,532 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-02-13
$607,448
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-02-13 | $607,448 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2026-01-13
$848,065x6
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2026-01-13 | $848,065x6 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2026-01-12
$547,927x21
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2026-01-12 | $547,927x21 | S | Form 4 |
|
ALNY
M
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Other
2025-11-17
$972,220
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Other
|
2025-11-17 | $972,220 | M | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
10b5-1 Sell
2025-11-17
$5,483,990Whalex11
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
10b5-1 Sell
|
2025-11-17 | $5,483,990Whalex11 | S | Form 4 |
|
ALNY
S
ALNYLAM PHARMACEUTICALS, INC.
Fitzgerald Kevin Joseph
• Officer • CSO & EVP, Head of Research
Sell to Cover
2025-10-02
$1,103,451Largex12
|
||||||
| ALNY |
ALNYLAM PHARMACEUTICALS, INC.
|
Officer • CSO & EVP, Head of Research
Sell to Cover
|
2025-10-02 | $1,103,451Largex12 | S | Form 4 |